Avestar Capital’s Kyntra Bio KYNB Stock Holding History

Avestar Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9	Closed	-$9K	–	404
2019 Q2	$9K	Hold	9	–	–	0.01%	512
2019 Q1	$11K	Buy	+9	New	+$12.2K	0.01%	467

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Avestar Capital's KYNB Position: Q3 2019 in Review

Avestar Capital sold out of Kyntra Bio (KYNB) in Q3 2019, closing a stake of 9 shares — an estimated $9K sold.

Avestar Capital first reported a position in KYNB in Q1 2019 and held it in 2 quarters. The position peaked at $11K in Q1 2019. 210 funds tracked by Wall St. Rank hold KYNB as of Q3 2019.

Avestar Capital reported no remaining Kyntra Bio position as of Q3 2019 after selling out during the quarter.
Avestar Capital sold 9 Kyntra Bio shares in Q3 2019, an estimated $9K.
Avestar Capital first reported a position in Kyntra Bio in Q1 2019 and held it in 2 quarters.
Avestar Capital's Kyntra Bio position peaked at $11K in Q1 2019.
210 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.